Nicholas Hoffman & Company LLC. Has $10.76 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Nicholas Hoffman & Company LLC. cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,880 shares of the company’s stock after selling 147 shares during the quarter. Eli Lilly and Company comprises 0.5% of Nicholas Hoffman & Company LLC.’s investment portfolio, making the stock its 18th largest holding. Nicholas Hoffman & Company LLC.’s holdings in Eli Lilly and Company were worth $10,756,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of LLY. Foster & Motley Inc. increased its position in shares of Eli Lilly and Company by 4.5% during the second quarter. Foster & Motley Inc. now owns 1,122 shares of the company’s stock valued at $1,016,000 after purchasing an additional 48 shares during the period. Impact Partnership Wealth LLC increased its position in shares of Eli Lilly and Company by 91.9% during the second quarter. Impact Partnership Wealth LLC now owns 881 shares of the company’s stock valued at $798,000 after purchasing an additional 422 shares during the period. Deseret Mutual Benefit Administrators increased its position in shares of Eli Lilly and Company by 1.7% during the second quarter. Deseret Mutual Benefit Administrators now owns 3,302 shares of the company’s stock valued at $2,990,000 after purchasing an additional 56 shares during the period. Mayflower Financial Advisors LLC increased its position in shares of Eli Lilly and Company by 2.2% during the second quarter. Mayflower Financial Advisors LLC now owns 3,098 shares of the company’s stock valued at $2,805,000 after purchasing an additional 66 shares during the period. Finally, Kapstone Financial Advisors LLC grew its position in Eli Lilly and Company by 9.7% in the second quarter. Kapstone Financial Advisors LLC now owns 510 shares of the company’s stock valued at $462,000 after acquiring an additional 45 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 2.5 %

Shares of Eli Lilly and Company stock traded down $24.08 during trading hours on Thursday, hitting $922.23. The company’s stock had a trading volume of 807,166 shares, compared to its average volume of 3,046,994. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $972.53. The stock has a 50 day moving average of $895.96 and a 200 day moving average of $826.05. The company has a market capitalization of $876.49 billion, a PE ratio of 138.08, a price-to-earnings-growth ratio of 2.91 and a beta of 0.41. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Analysts predict that Eli Lilly and Company will post 16.51 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.56%. Eli Lilly and Company’s payout ratio is presently 76.58%.

Analysts Set New Price Targets

A number of brokerages have weighed in on LLY. Wells Fargo & Company upped their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Morgan Stanley reiterated an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Bank of America upped their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Guggenheim upped their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Finally, Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price target for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. Two investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $961.76.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 75,510 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $860.78, for a total transaction of $64,997,497.80. Following the completion of the transaction, the insider now directly owns 97,793,810 shares in the company, valued at $84,178,955,771.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders sold 876,900 shares of company stock worth $788,605,032. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.